Table 3.

Discrimination capacity of dd-cfDNA and dd-cfDNA% for the diagnosis of BKPyVAN.

	Discrimination of proven BKPyVAN from resolving BKPyVAN		Discrimination of proven BKPyVAN from possible BKPyVAN		Discrimination of probable BKPyVAN from possible BKPyVAN		Discrimination of BKPyVAN# from non-BKPyVAN*
	dd-cfDNA > 8.06 ng/ml	dd-cfDNA% > 0.50	dd-cfDNA > 8.93 ng/ml	dd-cfDNA% > 0.84	dd-cfDNA > 9.06 ng/ml	dd-cfDNA% > 0.84	dd-cfDNA > 8.93 ng/ml	dd-cfDNA% > 0.84
AUC	0.965	0.760	0.943	0.653	0.957	0.963	0.956	0.745
Sensitivity	1.00	0.90	0.95	0.38	1.00	1.00	0.96	0.47
Specificity	0.91	0.61	0.83	0.91	0.83	0.91	0.87	0.91
PPV	0.95	0.80	0.90	0.88	0.64	0.78	0.88	0.85
NPV	1.00	0.78	0.90	0.46	1.00	1.00	0.95	0.63
PLR	11.50	2.30	5.46	4.31	5.75	11.50	7.34	5.38
NLR	0.00	0.16	0.06	0.68	0.00	0.00	0.05	0.58
DOR	420.00	14.00	90.25	6.30	33.25	73.50	150.00	9.24
Youden index	0.91	0.51	0.78	0.29	0.83	0.91	0.83	0.38

BKPyVAN, BK polyomavirus-associated nephropathy; BKPyV, BK polyomavirus; dd-cfDNA, donor-derived cell-free DNA; AUC, area under the receiver operating characteristics curve; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio.

^#BKPyVAN = proved BKPyVAN + probable BKPyVAN;

^*non-BKPyVAN = possible BKPyVAN + resolving BKPyVAN.